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Abstract
The vast majority of thyroid cancers of follicular origin (TC) 
have a very favourable outcome, but 5–10% of cases will de-
velop metastatic disease. Around 60–70% of this subset, 
hence less than 5% of all patients with TC, will become radio-
iodine refractory (RAI-R), with a significant negative impact 
on prognosis and a mean life expectancy of 3–5 years. Since 
no European expert consensus or guidance for this challeng-
ing condition is currently available, a task force of TC experts 
was nominated by the European Thyroid Association (ETA) 
to prepare this document based on the principles of clinical 
evidence. The task force started to work in September 2018 
and after several revision rounds, prepared a list of recom-
mendations to support the treatment and follow-up of pa-
tients with advanced TC. Criteria for advanced RAI-R TC were 
proposed, and the most appropriate diagnostic tools and 
the local, systemic and palliative treatments are described. 
Systemic therapy with multikinase inhibitors is fully dis-
cussed, including recommendations on how to start it and 
at which dosage, on the duration of treatment, and on the 
management of side effects. The appropriate relationship 
between the specialist and the patient/family as well as eth-
ical issues are covered. Based on the available studies and on 
personal experience, the experts provided 39 recommenda-
tions aimed to improve the management of advanced RAI-R 
TCs. Above all of them is the indication to treat and follow 
these patients in a specialized setting which allows the inter-
action between several specialists in a multidisciplinary 
team. © 2019 European Thyroid Association 
Published by S. Karger AG, Basel
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Premise
Few prospective studies are available on the manage-
ment of patients with advanced thyroid cancer (TC), and 
the decision making is mostly based on the personal ex-
perience of physicians. The present guidelines are mainly 
based on the knowledge derived from clinical practice of 
a group of ETA (European Thyroid Association) experts 
who regularly diagnose, treat, and follow up the most ag-
gressive forms of TC.
Epidemiology and Classification of TC
According to the European Network of Cancer Reg-
istries (https://www.encr.eu, January 2017), in Europe 
an estimated 53,000 TC cases were newly diagnosed in 
2012. In the same year, 6,300 Europeans are estimated to 
have died of TC. Women have a 3-fold higher estimated 
age-standardized rate of TC incidence (IRR) than men, 
with 9.3 and 3.1 cases per 100,000 person-years, respec-
tively (mean 6.3 cases). The same incidences are record-
ed in all developed countries, though in Europe there are 
wide regional differences. In particular, the highest esti-
mated age-standardized IRR are recorded in Lithuania 
(15.5 cases per 100,000 person-years), Italy (13.5), Aus-
tria (12.4), Croatia (11.4), and Luxembourg (11.1). The 
5-year relative survival of TC in Europe ranges from 80 
to 90%. TC includes histological types with extremely 
different prevalence. Among tumours originating from 
the follicular epithelium, differentiated TC (DTC) is the 
most common type and includes the papillary and fol-
licular histotypes, making up about 85–95% of all TCs, 
whereas Hürtle cell carcinomas (HC) and poorly differ-
entiated TC account for 2–5% each. Anaplastic thyroid 
carcinoma comprises approximately 1.7% of all cases of 
TC and is a very aggressive malignancy with an average 
survival time following diagnosis of 6 months or less. 
Finally, medullary TC, originating from the parafollicu-
lar C cells of neuroendocrine origin, accounts for 3–5% 
of all TCs. It can be classified as sporadic (75% of cases), 
or familial MTC. Familial forms are generally bilateral 
with multiple foci, are due to germline mutations in the 
RET gene and can associate with other diseases in the 
context of Multiple Endocrine Neoplasias, MEN 2A, and 
MEN 2B. 
These guidelines focus on radioiodine refractory (RAI-
R) TCs; hence, only TCs originating from the follicular 
epithelium and predicted to be capable of radioiodine up-
take, will be discussed.
Among DTCs, papillary TC (PTC) is the most com-
mon type, and it is defined as a malignant epithelial tu-
mour with evidence of follicular differentiation and a se-
ries of specific nuclear features. According to the last 
WHO classification [1], it can be sub-classified accord-
ing to the pathological features as papillary microcarci-
noma, as encapsulated, follicular, diffuse sclerotizing, tall 
cell, columnar cell, cribriform-morular, and hobnail cell 
variants, and as fibromatosis/fasciitis stroma, solid/tra-
becular, oncocytic, fusiform cell, clear cell and Warthin 
type variants. Follicular TC (FTC) is defined as a malig-
nant tumour lacking the nuclear characteristics of PTC. 
Three main subtypes are established: (1) minimally inva-
sive FTC (encapsulated and with invasion only of the 
capsule); (2) encapsulated angioinvasive FTC; and (3) 
widely invasive FTC. In the new classification of the 
WHO, HC or oncocytic tumours are regarded as a sepa-
rate group. The HC carcinomas are divided into mini-
mally invasive, encapsulated angioinvasive, and widely 
invasive subtypes, following the same criteria as those 
applied to FTC. Poorly differentiated thyroid carcinoma 
(PDTC) is a follicular neoplasm that shows limited evi-
dence of follicular cell differentiation, which lies mor-
phologically and behaviourally between differentiated 
(follicular and papillary) and anaplastic carcinomas [1]. 
The histopathological diagnostic criteria for PDTC are 
defined in the Turin Consensus proposal: (1) malignant 
thyroid follicular cell neoplasm (presence of invasion 
and/or metastasis); (2) solid, trabecular, or insular growth 
pattern; (3) absence of the conventional nuclear features 
of PTC; (4) at least one of the following three features: 
convoluted nuclei (defined as a small round hyperchro-
matic nuclei with convolutions of the nuclear mem-
brane), 3 or more than 3 mitoses per 10 high-power 
fields, and tumour necrosis [2]. Vascular invasion, lymph 
node metastases, extrathyroidal tumour extension are 
very common in PDTC, and distant metastases may be 
detected at presentation or shortly after initial diagnosis 
[3, 4]. PDTCs are frequently resistant to radioactive io-
dine, and have a 5-year overall survival rate of 60–85% 
[5]. PDTC with predominant oncocytic features defines 
the oncocytic variant of PDTC, which is characterized by 
an even poorer prognosis in terms of overall and tumour-
specific survival [6].
DTCs, HCs, or PDTCs which, during tumour progres-
sion, lose their ability to uptake and concentrate radioio-
dine, and in some cases to produce thyroglobulin (Tg), 
are commonly clinically defined as dedifferentiated TCs 
(DeDTC). DeDTC is not a histopathological entity and 
can be thus diagnosed only during the course of the dis-
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ease. Indeed, current WHO classification does not pre-
cisely define the pathological criteria of dedifferentiation, 
though pathologists refer to this term when they observe 
signs of dedifferentiation in nuclei, in the growth pattern, 
a high mitotic activity, and necrosis in the recurrent or 
metastatic lesion of a patient with primary diagnosis of 
DTC [5, 7, 8].
The molecular pattern of DTCs is often characterized 
by mutations in the MAPK and PI3K pathways, preva-
lently BRAF and RAS mutations in PTC and RAS and 
PAX8/PPARγ mutations in FTC [9]. During the dedif-
ferentiation process, DTCs acquire subsequent muta-
tions, and they frequently harbour, as PDTC, multiple so-
matic genetic alterations including TERT promoter and 
EIF1AX mutations [10, 11].
In terms of mortality, the IRR are 0.7 and 0.5 cases per 
100,000 person-years for women and men, respectively 
(mean 0.6 deaths). The vast majority of TCs have an ex-
cellent prognosis, but 5–10% of cases (6–7 new cases/
year/million) will develop metastatic disease, mostly lo-
cated in lungs and bones. The prognosis of these meta-
static cases remains favourable as long as they maintain a 
response to the treatment with radioiodine. Unfortunate-
ly, around 60–70% of this subset, still less than 5% of all 
patients with TC, will become RAI-R, representing 4–5 
new cases/year/million. This has a significant impact on 
prognosis, with the 10-year survival rate dropping to less 
than 20% and the mean life expectancy to 3–5 years once 
the disease is RAI-R [12].
Recommendation
[R1] The development of dedifferentiation and RAI refractori-
ness during the course of the DTC should be taken into consider-
ation. 
[R2] Poorly differentiated TC is frequently RAI-R and har-
bours a high risk of recurrent or metastatic disease and cancer-
related death.
[R3] RAI refractoriness occurs in around 60–70% of metastat-
ic TCs, but less than 5% of all patients with TC.
Definition of RAI-R TC 
In recent years, many new drugs have been investi-
gated for the treatment of progressive RAI-R TC. Cur-
rently, 2 multikinase inhibitors (MKI) have been ap-
proved for treatment by the Food and Drug Administra-
tion (FDA) and the European Medicines Agency (EMA), 
e.g. sorafenib and lenvatinib. The efficacy of both drugs 
has been demonstrated in phase III studies (DECISION 
study for sorafenib [13] and SELECT study for lenvatinib 
[14] and has been confirmed in “real-life” studies [15–
19].
Although criteria for prescribing both MKIs include 
RAI-R disease and progression, the definition of both 
categories can be challenging in clinical practice. In in-
ternational guidelines [20] and scientific publications 
[14, 20–30], there is no consensus on the definition of 
RAI-R disease. In most publications, the following cate-
gories are proposed: (1) the absence of uptake of RAI in 
all lesions on scintigraphy; (2) the absence of RAI uptake 
in some but not all lesions; (3) progression despite uptake 
of RAI; (4) reaching the maximum recommended activ-
ity of RAI. 
Absence of Uptake of RAI on Scintigraphy
Publications differ in their criteria for absence of RAI 
uptake on scintigraphy, some stating post-RAI therapy 
scintigraphy [13, 14, 20], others diagnostic scintigraphy 
or both [25, 27]. It should be noted that diagnostic scin-
tigraphy, even with I-124, is inferior to post-therapeutic 
scintigraphy [31]. In addition, factors that influence RAI 
uptake, including patient preparation, administered ac-
tivity, and scanning protocols are often not specified, 
though these factors may influence RAI accumulation by 
the tumour and the sensitivity of detection [28]. In con-
trast, the presence of RAI uptake does not guarantee RAI-
sensitive disease [32, 33].
Absence of RAI Uptake in Some but Not All Lesions
Although a mixed pattern with some lesions accumu-
lating RAI and others not is also considered RAI refrac-
tory disease in most publications, it is uncertain whether 
this is correct, as no study has shown that continuation of 
RAI treatment in this situation is not beneficial. A com-
bination of RAI therapy for RAI-avid lesions and local 
treatment for one or a limited number of RAI refractory 
lesions may be considered in certain patients. 
Progression despite Uptake of RAI
Although most publications agree that progression is 
a criterion for RAI-R disease, huge variation exists in the 
definition of progression. Radiological progression is 
widely accepted as an important criterion, but some stud-
ies also include biochemical progression [20, 25, 27]. 
Metrics for radiological progression are not specified in 
most publications. In clinical trials, RECIST 1.1 criteria 
[34] are strictly followed to define progression. Neverthe-
less, it should be noted that these criteria are not designed 
Fugazzola/Elisei/Fuhrer/Jarzab/
Leboulleux/Newbold/Smit
Eur Thyroid J 2019;8:227–245230
DOI: 10.1159/000502229
for individual patient care since progression, as defined 
by RECIST, is not identical to clinically relevant progres-
sion. As an example, the appearance of a small new lesion 
is technically defined as radiological progression, but can 
be clinically irrelevant. On the other hand, even a minor 
increase in volume can have a major clinical impact de-
pending on the anatomical position of the metastatic le-
sion. A second uncertainty in defining progression is pro-
gression rate. In most publications, there is no time frame 
indicated concerning progression. In the DECISION and 
SELECT trials, time periods were defined as 14 and 12 
months, respectively [12, 13], some publications mention 
intervals of 6–12 months, whereas others do not specify 
time frames. 
Reaching the Maximum Activity of RAI
In a study from France, it was observed that after a 
cumulative activity of 22.2 GBq, no further complete re-
missions were achieved in patients with metastasized 
TC [12]. Hence, it was concluded that further RAI treat-
ment exceeding 22 GBq would not be beneficial. How-
ever, this conclusion, based on one study, cannot be 
translated into a universal cut-off value for RAI activity. 
For instance, if a patient has stable disease after multiple 
therapies with RAI, this should not be regarded as RAI-
R disease, as is acknowledged in the ATA guidelines 
[20].
Recommendation
[R4] In patients with radiologically proven lesions, RAI-R dis-
ease is almost certain in the absence of RAI uptake on SPECT-CT, 
performed after high-activity RAI and prepared with high TSH 
and a diet with low iodine content. 
[R5] The question of whether to continue with RAI therapy or 
not in a patient without RAI uptake, or with a mixed pattern of 
uptake, or progressing despite RAI uptake, can only be addressed 
in a multidisciplinary team (MDT), weighing the benefits and dis-
advantages of continuing RAI eventually combined with local 
treatments. 
[R6] The question of whether RAI therapy should be continued 
in patients who have received multiple treatments with RAI can 
only be addressed in an MDT, weighing the benefits and disadvan-
tages of continuing RAI. 
[R7] Progression should be defined as radiological progression, 
according to RECIST 1.1 criteria, within a clinically relevant time 
frame, which is usually considered 6–12 months. Tg can be used 
as an indicator for progression, but not as a surrogate for radio-
logical assessment. The question whether progression is clinically 
meaningful cannot be answered from the literature and should be 
addressed in an MDT.
Diagnostic Tools
Diagnostics in advanced TC are directed to assess tu-
mour biology and tumour burden. Clinical examination 
will clarify to what extent the patient is affected by local 
and distant tumour manifestations, e.g. tracheal and/or 
oesophageal compression, metastases to bone, lung, and 
brain. It should also include assessment of general symp-
toms such as pain, fatigue, changes in weight and appe-
tite, and importantly the impact of disease on daily life. 
The latter is critical in relation to treatment with MKIs 
since side effects may significantly impact daily activities 
in an otherwise asymptomatic patient. 
Tumour biology comprises the histological and mo-
lecular features of TC, its functional properties, in par-
ticular the ability to concentrate iodine in a therapeuti-
cally relevant manner, and the rate of tumour growth. 
The contribution of pathology to determining tumour 
biology resides on two principles: first, a careful review 
of the initial histopathology and, if required, a second as-
sessment by a thyroid reference pathologist may both 
help to understand the aggressive disease course ob-
served. Second, molecular pathology, in particular 
screening for BRAF mutations and ALK, NTRK, RET 
rearrangements may have a therapeutic impact, e.g. for 
considering targeted treatment. Furthermore, while sev-
eral studies suggest that the presence of a TERT promot-
er mutation (or Tp53 mutation) in TC is associated with 
a worse prognosis and hence a higher rate of these muta-
tions can be expected in advanced TC [35, 36], there is 
no evidence that presence of either mutation should alter 
or determine management. Clearly, incorporating mo-
lecular pathology into treatment decisions is a hot topic 
for research activities, that also includes pharmacological 
approaches aimed at restoring therapeutically useful 
131-I uptake and lately immunotherapy [37]. In this con-
text, genetic analyses should be directed to the evaluation 
of alterations targeted by drugs either approved or on 
trial. 
The importance of high-resolution imaging and the 
lack of absolute criteria to define a TC as RAI-R have re-
cently been discussed in the “Martinique principles” – a 
joint statement by EANM ATA, ETA, and SNMI [30]. 
Until better evidence is available from study data, the cri-
teria discussed above for a likely RAI-R TC may be used 
(see the section Definition of RAI-R TC). 
Tumour growth is assessed by sequential CT scan-
ning, most commonly at 6- to 12-month intervals and 
applying RECIST 1.1 criteria to determine disease status. 
Recently, Tuttle and co-workers [38, 39] proposed that 
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changes in lesion volume, e.g. in lung metastases, may be 
a more reliable prognostic marker for tumour growth 
than RECIST and may possibly facilitate the decision 
when to start MKI therapy. In addition to morphological 
imaging, important prognostic indicators may be de-
rived from FDG-PET/CT. In a pilot study, TC patients 
with FDG-PET-positive tumour lesions had a signifi-
cantly shorter survival than patients with metastatic TC, 
but no increased glucose uptake [40]. Furthermore, by 
comparison with RAI avidity, FDG positivity had a more 
profound negative impact on survival, as confirmed in an 
independent second study [41]. 
Tumour burden describes the total tumour mass in 
the body. Its assessment should be based on imaging in-
cluding high-resolution neck ultrasonography, or CT 
scanning of neck, chest, abdomen, and brain, in addition 
to assessment for bone metastases by scintigraphy and 
CT. Alternatively and due to its prognostic impact, FDG-
PET/CT scanning should be considered in RAI-R dis-
ease. Moreover, focused diagnostics, e.g. bronchoscopy 
or oesophagoduodenoscopy, may be indicated to clarify 
local tumour extension with current, imminent, or likely 
complications. Tumour burden can be roughly estimat-
ed by Tg levels, as well as the rapid progression and poor 
prognosis of the disease can be predicted by a Tg dou-
bling time < 1 year [42]. However, in some aggressive TC, 
with a poor level of Tg secretion, Tg level might under-
estimate tumour burden. Furthermore, in the presence 
of TgAb, Tg cannot be used as a reliable tumour marker. 
It is worth noting that in patients with advanced TC, 
rhTSH test is not performed since data on the Tg-stimu-
lated levels do not add any additional relevant informa-
tion for the management of these patients. 
All patients with advanced TCs require control of 
their thyroid function in order to maintain suppressed 
TSH levels. Thus, TSH and fT4 serum concentrations 
should be obtained at 6- to 12-month intervals and more 
frequently if MKI treatment is started. In case of postop-
erative hypoparathyroidism, regular control of calcium 
status is required following the recent recommendations 
of the American Thyroid Association [43]. 
Importantly, while all of the discussed diagnostic ap-
proaches and their outcomes are linked, none of them 
provides a “one and only” information; hence, a combi-
nation of diagnostic tools and their interpretation by 
physicians experienced in TC care is required to unmask 
the true nature of advanced TC and to enhance patient-
oriented decision making. 
Recommendation
[R8] A careful clinical assessment is recommended at every fol-
low-up visit. Particular attention should be paid to clinical mani-
festations of advanced disease and quality of life. 
[R9] Laboratory assessment should include TSH, fT4, and cal-
cium status in case of postoperative hypoparathyroidism. Tg and 
Tg antibody titre should be assessed using the locally available Tg 
assay and relying on dynamics in sequential measurements rather 
than absolute Tg concentrations. A change in assays should be 
avoided. 
[R10] In advanced TC, serial imaging at 6- to 12-month inter-
vals, e.g. with whole-body CT and applying RECIST, is useful to 
assess dynamics of tumour growth. 18-FDG-PET/CT scanning 
may yield additional information on tumour biology with a nega-
tive prognostic impact for lesions with increased glucose uptake.
[R11] No single imaging modality provides “one and all” infor-
mation on tumour biology; hence, a combination of imaging tech-
niques and where indicated, other diagnostics, e.g. endoscopy, are 
required to unravel which tumour lesions require local or system-
ic intervention. 
[R12] Histopathology together with molecular pathology may 
be predictive of the course of TC, but so far has limited impact on 
management. However, molecular pathology may be useful for in-
dividualized, off-label targeted therapies, when no clinical studies 
are available. 
[R13] Interpretation of all diagnostics investigations that con-
tribute to the assessment of advanced TC biology requires a mul-
tidisciplinary board of physicians with expertise in endocrinology, 
endocrine oncology, endocrine surgery, radiologist, nuclear med-
icine, and pathology.
Local Treatments
Before starting systemic therapy with MKIs, a careful 
analysis of some clinical features of the patient, such as 
age and general health conditions, as well as some consid-
erations about the number, the size, the site, and the rate 
of growth of the lesions should be performed. The reason 
for this reappraisal is related to the awareness of the neg-
ative impact of these drugs on the quality of life of pa-
tients. As a consequence, whenever possible a local treat-
ment, including surgery, should be preferred, and sys-
temic therapy should be postponed until evidence of a 
multimetastatic progressive disease (Fig. 1). The possibil-
ity of using the same types of local treatments should be 
considered also when the patient is already receiving MKI 
treatment with a good control of the majority of systemic 
disease with the exception of only one lesion. In this case, 
a specific locally ablative therapy directed at the growing 
lesion can be considered without necessarily interrupting 
MKI treatment temporarily. The most common types of 
local treatments, other than surgery, are reported below.
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External Beam Radiotherapy
Although RAI-R TC are not very sensitive to radiation, 
external beam radiotherapy (EBRT) may be indicated in 
some specific cases [44]. The primary objective of EBRT 
in these tumours is to stop the growth or at least to reduce 
the rate of growth in order to control or prevent symp-
toms. For this reason, EBRT can be used for the treatment 
of inoperable primary or locally recurrent TC. Similarly, 
it can be considered in case of recurrent lymph node me-
tastases after repetitive surgery. EBRT is associated with 
improved local disease control and a longer progression-
free survival time [45, 46]. With the same medical objec-
tive, but also to reduce the pain, EBRT can be used in bone 
metastases. Brain metastases may be also treated with 
EBRT, with a stereotactic radiosurgery and/or whole-
brain radiotherapy, and a rapid and reliable response may 
be obtained. The recent introduction of stereotactic EBRT 
has opened up the possibility of treating small metastatic 
lesions in any organ including lungs, for which a diffuse 
radiation exposure is contraindicated due to the high risk 
of radiation fibrosis and respiratory dysfunction [47].
Treatment of Tracheal Infiltration or Compression
When the trachea is infiltrated and tumour invasion of 
the tracheal lumen is found at bronchoscopy, an ablative 
laser treatment to minimize obstruction can be per-
formed. If necessary, this treatment can be periodically 
repeated, possibly not more frequently than every 6 
months. This treatment should be preferred to EBRT of 
the trachea in patients who are candidates for MKI treat-
ment, since, in real life, patients previously submitted to 
external radiotherapy seem to be at risk to develop an ir-
reparable fistula (Fig. 2). If the trachea is not infiltrated 
but progressively compressed by the local tumour mass, 
an endotracheal stent may be applied to reduce the risk of 
suffocation [48].
Metastasectomy of Bone and Lung Metastases
With the improvement of surgical skills and tech-
niques, bone metastases (e.g., vertebral lesions) can be 
safely removed [49]. Similarly, selected lung nodules can 
be removed under thoracoscopy without surgical mor-
bidity [50].
Percutaneous Interventional Techniques
They can be classified as vascular, ablative or consoli-
dative treatments. The vascular techniques include the 
trans-arterial embolization and the transarterial chemo-
embolization (TACE) and exploit the hyper-vascular 
characteristic of the TC visceral or bone metastases. The 
ablative techniques are applied to achieve partial or com-
plete necrosis of the neoplastic tissue by causing a dra-
matic increase (≥55   ° C in radiofrequency) or decrease 
(around –40   ° C through cryoablation) of the intra-tu-
moral temperature in the visceral or bone metastases. The 
necrotic process can be also achieved by the ultrasound-
guided ethanol injection, usually in metastatic lymph 
nodes. Finally, the consolidative techniques are specifi-
cally applied for the treatment of the lytic bone metastases 
in order to prevent a pathological fracture. All the above-
Progression of one single lesion
or multiple lesions in one single organ
Progression of multiple lesions
or single lesions but in multiple organs
Local treatment(s)
if feasible
Progressive
RAI-R TC
Slow growth
(<20% in 12–14 months)
Rapid growth
(according to RECIST)
Wait and see
(4–6 months controls)
Systemic therapy
(MKI)
Fig. 1. Algorithm for decision making when a radioiodine refractory (RAI-R) thyroid cancer (TC) is progressing.
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mentioned treatments can be combined and tailored ac-
cording to the specific needs of the patient [51]. Some of 
them are more detailed below. 
Conventional TACE
This technique is commonly used for palliative treat-
ment of advanced hepatocellular carcinoma, but in some 
advanced cases of liver metastatic disease can also be ap-
plied in other human tumours including advanced TC. 
This procedure seems to have a clinical benefit when liv-
er metastases are smaller than 3 cm and liver involvement 
is less than 30%. It is yet unproven if conventional TACE 
used in selected patients with advanced TC is really effec-
tive at prolonging survival or at least progression-free 
survival [52]. Cases are relatively rare, and a prospective 
study is still missing [52]. Recently, the transarterial de-
livery of Y90 radiolabelled resin microspheres, named ra-
dioembolization (or cTARE), has been successfully intro-
duced into clinical practice for treatment of hepatocellu-
lar carcinoma and neuroendocrine tumours, but studies 
on liver metastasis of RAI-R TC are missing [53].
Radiofrequency Thermoablation
This procedure is based on the use of electromagnetic 
waves that induce movement and consequently the pro-
duction of heat to destroy tumour cells. The technique 
was initially developed for the treatment of primary and 
metastatic liver malignancies [54]. This treatment can be 
applied to local disease, such as metastatic lymph nodes 
but also to bone, liver, and lung lesions, if technically pos-
sible and clinically indicated. Thus, it might be performed 
when the lesion to be treated is the only site of disease or 
the only one amongst others that is growing, and where 
there is no surgical option. Radiofrequency thermoabla-
tion is a safe procedure to treat the viable tumour tissue 
and to reduce the volume of a metastatic lesion [55], 
which can be afterwards submitted to surgical removal.
Ultrasound-Guided Percutaneous Ethanol Ablation
In case of neck relapse, small metastatic lymph nodes 
< 1.0–1.5 cm can be frequently found. If smaller than 1.5 
cm in the largest diameter, they can just be periodically 
observed (every 6–12 months) until the evidence of a sta-
ble volume and a stable number. If growing, they can be 
successfully and safely treated with ultrasound-guided 
percutaneous ethanol ablation that can be repeated in 
case of recurrence [56]. This procedure is often manage-
able at ambulatory level, does not require hospitalization, 
and has a very low cost. However, it is worth to note that 
in advanced and progressive TC, neck lymph node me-
tastases are often a negligible problem compared to the 
other types of metastases, and therefore observation may 
be sufficient. 
Cementoplasty of Bone Metastases
It is a palliative treatment for osteolytic bone metasta-
ses, to be performed alone or in combination with other 
local treatments, such as radiofrequency ablation or 
EBRT. Its aim is to obtain the reinforcement of bone de-
fect through percutaneous injection of polymethylmeth-
acrylate cement. This minimally invasive technique can 
be performed in any metastatic site and results in signifi-
cant pain relief, offering stability of the affected bones 
[57].
Fig. 2. Tracheal fistula (indicated by the 
white arrow) which occurred after 2 
months of treatment with lenvatinib in a 
patient with advanced RAI-R TC.
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Recommendation
[R14] If the progression is limited to a single lesion or more 
than one lesion within the same organ, the possibility of perform-
ing a local treatment should be considered.
[R15] Local treatment can be also done during systemic thera-
py if only a single lesion starts to grow. In this case, local therapy 
can be considered without interrupting MKI treatment temporar-
ily or withdrawing it just for few days. 
When to Start Treatment with MKIs?
The conclusion that a patient has RAI-R disease and/
or disease progression should not automatically lead to 
the initiation of treatment with MKI. In answering the 
question whether or not initiation of MKI is beneficial, 
the following questions are relevant.
Tumour Load
Currently, no studies have been published on the rela-
tionship between tumour load and efficacy of MKIs. Sub-
group analyses of the DECISION and SELECT studies 
indicated that sorafenib and lenvatinib were more effec-
tive in smaller tumours [13, 14, 58]; however, no definite 
cut-off level with respect to tumour size can be derived 
from the literature. 
Symptoms
No studies are available on the relationship between 
clinical symptoms and efficacy of MKIs. Subgroup anal-
yses of the DECISION and SELECT studies did not show 
differences in efficacy in relation to the presence of symp-
toms [13, 14]. Consequently, it cannot be concluded 
from the literature if an MKI should be initiated before 
the occurrence of clinical symptoms or when clinical 
symptoms have occurred. However, ECOG is a major 
criterion with treatment being more efficient in patients 
with ECOG 0–1. Currently, an international prospective 
observational trial is being performed to address this is-
sue [59].
Location of Metastases
No relationship has currently been identified between 
location of metastases and efficacy of MKIs. Subgroup 
analyses of the DECISION and SELECT studies did not 
show differences in efficacy in relation to location of me-
tastases [13, 14]. Brain and liver metastases might be less 
responsive than other sites [58].
Age
In a sub-analysis of the SELECT trial by Brose et al. 
[60], the safety and efficacy of treatment with lenvatinib 
were compared between a group of patients with a me-
dian age of 56 years, and a group of older patients with a 
median age of 71 years. The incidence of severe treat-
ment-related adverse events (AEs) was significantly high-
er in older patients versus younger patients (89 vs. 67%, 
respectively; p < 0 .001). Older patients were also more 
likely to experience AEs requiring dose modifications, 
and they received a lower median daily dose, though no 
significant difference was observed in progression-free 
survival between the two groups. This highlights the im-
portance to accurately evaluate risks and benefits of MKI 
treatment in each patient. 
Genetic Profile
Although MKIs have distinct in vitro activity in rela-
tion to molecular targets, no clear relationships have been 
identified between genetic profiles of TC in patients and 
efficacy of drugs. Subgroup analyses of the DECISION 
and SELECT studies did not show differences in efficacy 
in relation to BRAF or RAS genetic alterations [13, 14]. 
The absence of these relationships can be explained by 
many factors, including the fact that only primary tu-
mours have been included in genetic analyses, the exis-
tence of heterogeneity in terms of genetic profiles be-
tween metastases within one patient, many other factors 
that influence tumour growth, pharmacodynamics as-
pects, and the fact that neither sorafenib nor lenvatinib 
target a specific TC oncogene, but rather exert anti-angio-
genic effects.
The decision on when to start treatment with MKIs 
should be addressed in an MDT, weighing all the benefits 
and disadvantages. 
Recommendation
[R16] As currently no curative drug treatments for RAI-R TC 
are present, and MKIs are accompanied by side effects, experts 
agree that treatment with MKIs should only be considered in pa-
tients with progressive RAI-R disease, with considerable tumour 
load and when, according to a multidisciplinary group of experts, 
refraining from treatment with MKIs would lead to considerable 
harm/clinical complications within the near future. Before starting 
MKIs, local treatments should be considered. 
[R17] The decision to start MKIs should include patient-relat-
ed medical factors (age, health status, comorbidities, and contra-
indications) and patient preferences with respect to treatment 
goals and values, and acceptance of adverse effects.
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Dosage
Following the DECISION trial, approval for sorafenib 
was given at the dosage of 400 mg (2 × 200-mg tablets) 
twice daily (adult patients) [13]. The drug should be tak-
en 12 h apart, without food, at least 1 h before or 2 h after 
a meal. Following the SELECT trial, approval for lenva-
tinib was given at the dosage of 24 mg (2 × 10-mg and 1 
× 4-mg tablets), once daily (adult patients) [14]. Capsules 
can be swallowed whole or, in selected cases, they can be 
dissolved in a small amount of water and administered 
with or without food intake. In case of severe renal im-
pairment (creatinine clearance less than 30 mL/min cal-
culated by the Cockcroft-Gault equation using actual 
body weight), or in case of severe hepatic impairment 
(Child-Pugh C), the recommended dosage of lenvatinib 
for DTC patients is 14 mg orally once. 
Globally, in case of grade 3 or grade 4 AEs, it is recom-
mended to withhold the drug until improvement to 
grade 0 or 1 or baseline and then to either resume at a 
reduced dose or to discontinue. However, this depends 
on the type of AE, and in some cases such as fistulas, it is 
recommended to withdraw permanently. For sorafenib, 
dosage may be reduced to 400 mg once daily or to a sin-
gle 400 mg dose every other day. For lenvatinib, first re-
duction is to 20 mg, second to 14 mg, third to 10 mg. 
There are no data on the use of sorafenib in children, 
whereas lenvatinib was given in children at the dose of 14 
mg/m2 [61]. 
Data from the phase III trials showed that 64% of the 
patients under sorafenib and 68% of the patients under 
lenvatinib needed a dose reduction, 66% of the patients 
under sorafenib and 88% of the patients under lenvatinib 
required a temporary dose interruption, and 19% of the 
patients under sorafenib and 14% under lenvatinib need-
ed withdrawal due to side effects. Overall, the mean dose 
of sorafenib received was 651 mg/day, and the mean dose 
of lenvatinib received was 17.2 mg/day. Although for len-
vatinib a correlation was shown between the drug expo-
sure and the percent of tumour size decrease [62], it 
should be noted that patients over the age of 65 years old, 
who represent the majority of patients with advanced 
TC, have more AEs than those < 65 years old [60]. Based 
on these results, the question of starting lenvatinib at a 
lower dosage has been raised, a prospective phase II trial 
is ongoing comparing the dosage of 24 mg with 18 mg, 
in order to evaluate if starting lenvatinib at a lower dos-
age decreases secondary effects without altering treat-
ment efficacy (#NCT02702388).
Recommendation
[R18] With the exception of patients with severe renal or liver 
dysfunction, treatment should be started at the approved dosage. 
However, active management of AEs should be organized in order 
to decrease the dose in case of AE. Special attention should be giv-
en to older patients because of a higher rate of AEs.
How to Advise the Patient and the Family
Decisions regarding the management of advanced 
RAI-R TCs are complicated and challenging for the pa-
tient and the medical team. As in all situations in medi-
cine, a careful decision making process involving medi-
cal, emotional, social, and spiritual factors is essential to 
find the optimal approach for a patient. In this process, 
the following elements can be identified: inventory, de-
velopment of management plans, information, decision 
making. These elements are addressed separately, but will 
in most cases take place in parallel. 
History
Before management proposals can be formulated, in-
formation should be collected on the following items: (a) 
The medical state of the patient, including the disease sta-
tus, physical performance, presence of comorbidities and 
co-medication. (b) The emotional situation of the patient. 
What is the degree of anxiety? Is there depression? (c) The 
social situation of the patient, including dependency, 
competences and vulnerabilities and the supportive net-
work. (d) The personal expectations, perspectives, goals, 
and needs of the patient.
Development of Management Plans
Based on the above-mentioned information, integral 
management plans can be designed, not only focussing 
on medical management (including symptomatic and 
palliative treatment), but also addressing the social, emo-
tional, and spiritual needs of the patient. The problem 
with developing medical plans is that there is limited evi-
dence based on clinical studies that can be translated di-
rectly to the situation of the individual patient. As a con-
sequence, developing these plans is based mostly on ex-
pert opinion and the experience of a MDT in which all 
healthcare specialists are represented, not restricted to 
medical specialists, but also general practitioners, social, 
psychological, and spiritual caregivers. 
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Information
The patient will be informed on the items that have 
been inventoried as well as the treatment scenarios that 
have been proposed. The patient will be informed on ben-
efits and disadvantages of the different proposals. Based 
on the input of the patient, scenarios can be adapted or 
new options developed. The amount of information that 
a patient is able to process depends of course on her/his 
emotional state but also on her/his capabilities. It is best 
when a patient is accompanied by relatives during these 
contacts.
Decision Making
All decisions in medicine, with the exception probably 
of acute, life-threatening conditions, are shared deci-
sions, meaning that opinions of patients and healthcare 
professionals are brought together. In the end, the patient 
is the person who has to make a decision, but the role of 
the patient in the process of decision making may vary 
greatly. Most patients however, do not want to receive 
only data and facts, but expect a clear preference from 
their doctors. Patients will need time to weigh all the in-
formation and management options and often want to 
consult relatives or experts. 
Recommendation
[R19] Gather extensive information on the patients’ psycho-
physical status before formulating management proposals. 
[R20] Develop management plans mostly based on expert 
opinion of an MDT. 
[R21] Inform patient and relatives on benefits and disadvan-
tages of the different available management plans and together de-
cide on appropriate management for the individual patient.
Duration of Treatment and Follow-Up
Duration of Treatment
Tyrosine kinase inhibitors are cytostatic, and not cy-
totoxic drugs; thus, they exert a break to the cell growth 
that can restart immediately when the break is removed 
[63, 64]. This is the rationale why an MKI therapy should 
be continued until the evidence of no further clinical 
benefit. The concept of clinical benefit is not well de-
fined, but we can recapitulate it according to a series of 
clinical factors such as: (a) the evidence of partial remis-
sion or stabilization of the tumour burden, (b) the im-
provement of symptoms, (c) the slow progression of the 
disease or the progression of only one lesion while the 
others are stable. Moreover, there is evidence, at least for 
sorafenib, that patients who entered into progression 
and continued to be treated with the drug showed a slow-
er progression than those who stopped the drug [25]. On 
the basis of this evidence, the best option for the patient 
is to continue the drug at least until the evidence that a 
second line of MKI or a clinical trial with new experi-
mental drugs is available and, at this point, it could be 
useful to switch the therapy [64, 65]. Sometimes, MKI 
therapy leads to severe side effects and if the degree of 
severity, according to the Common Terminology Crite-
ria for Adverse Events (CTCAE) scale, is ≥3, the drug 
must be stopped until recovery from the side effects, but 
then it should be restarted at a lower daily dose. How-
ever, patients must be clearly instructed to report side 
effects even when they are still low grade in order to avoid 
MKI interruption. Overall dose reduction, which can be 
effective when a side effect is still low grade, should be 
preferred. The final objective is to find a daily dose that 
can provide a good balance between the quality of life of 
the patient and the positive effect of the drug.
Follow-Up
The follow-up of patients treated with MKI is crucial 
to the success of this therapy. In particular, it is funda-
mental that the patients have a facilitated access to reach 
either specialist doctors or nurses who must have been 
trained to follow them with their specific clinical and psy-
chological problems. Patients treated with MKIs must be 
strictly followed especially during the first 6 months of 
therapy. This need is related to the multiple side effects 
that the patients can experience (see also the section Man-
agement of Side Effects). Blood pressure should be well 
controlled before starting the MKI, especially when start-
ing lenvatinib [14]: if pathologically altered or even if bor-
derline, a specific therapy must be started and then tight-
ly controlled. Patients must be educated in doing this by 
him/herself, and a daily record should be kept in form of 
a diary to show to doctors or nurses at each control. A 
similar approach should be taken for prevention of pal-
mar-plantar erythrodysaesthesia (“hand and foot syn-
drome”) when sorafenib is started [13]. Patients should 
be educated in preventive care of hands and feet with ad-
equate procedures and periodic controls by physicians or 
specialist nurses. Patients must also be taught to report 
any side effect as soon as possible, and for this reason they 
must have a direct access for communication with the 
doctors or specialist nurses. 
Other than this advice, patients should meet their spe-
cialist’s team every 2 weeks for the first 2 months. During 
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these visits, body weight must be controlled tightly to ver-
ify weight loss as a frequent consequence of MKI (i.e., due 
to anorexia, dysgeusia, mucositis, etc.) (see also the sec-
tion Management of Side Effects). Furthermore, controls 
must include blood pressure measurement and clinical 
chemistry, in particular TSH and electrolytes, which can 
be severely altered by MKIs (Table 1). An ECG must be 
also performed to verify the QTc, especially when lenva-
tinib is administered. 
Two to 3 months after the initiation of the MKI ther-
apy, an appropriate imaging (usually by CT and/or MRI) 
should be performed to verify the response to the drug. 
An 18-FDG PET/CT could also be useful to verify the re-
duction of the metabolic activity of the metastatic lesions, 
though whether this has a prognostic or management im-
pact still needs to be demonstrated. During these visits, a 
measurement of serum Tg concentrations and Tg anti-
bodies should be done and evaluated together with the 
results of the imaging. 
After the first 2 months, the follow-up visits may take 
place at monthly intervals until the 6th month and then 
every 3 months until the completion of the 1st year of 
MKI treatment. Afterwards, if patients are stable, follow-
up intervals can be extended to 4 months with periodical 
imaging. The levels and the trend of the serum Tg can be 
very useful to plan the timing of the controls and in par-
ticular of the imaging. 
Recommendation
[R22] MKI treatment should be continued as long as there is 
evidence of clinical benefit. 
[R23] MKI should be stopped only when another therapeutic 
option is available or the side effects are intolerable or treatment is 
no longer providing clinical benefit or at patients’ request.
[R24] In case of side effects, MKI daily dose should be reduced 
to maintain a balance between a good quality of life and control of 
disease.
[R25] Patients must be strictly followed during the first 2 
months of therapy with blood tests, ECG, and clinical monitoring.
[R26] After 2–3 months of therapy, a first imaging evaluation 
should be performed to verify the effectiveness of MKI. 
[R27] Follow-up visits should be performed every 2 weeks dur-
ing the first 2 months of MKI therapy, and then every month until 
the first 6 months, every 3 months within the first year, and after 
that every 4 months. 
Management of Side Effects
Virtually all MKI-treated patients experience at least 
one or more AE. The severity of AEs is commonly scored 
according to Common Terminology Criteria for Adverse 
Events (CTCAE version 4.03 can be downloaded with- 
out charge at https://evs.nci.nih.gov/ftp1/CTCAE/CT-
C A E _ 4 . 0 3 / C T C A E _ 4 . 0 3 _ 2 0 1 0 - 0 6 - 1 4 _
QuickReference_8.5x11.pdf. Although most AEs are 
manageable, some of them are potentially serious and 
rare, or unreported adverse effects, possibly life-threaten-
ing, could occur. Interestingly, AEs are less frequent in 
patients < 65 years of age [60]. The most frequent AEs for 
the 2 MKIs most widely used in Europe, sorafenib and 
lenvatinib, are reported in Table 2. 
In the majority of cases, the frequency of the AEs re-
ported in the phase II [66, 67] and in the phase III regis-
tration (DECISION and SELECT) studies [13, 14] cor-
responds to the frequency found in the subsequent real-
life studies. Among the most frequent AEs (≥50% of 
patients), are hypertension, particularly in patients tak-
ing lenvatinib, diarrhoea, weight loss, and fatigue. Der-
matological AEs, such as palmar-plantar erythrodysaes-
thesia syndrome, skin rash, and alopecia are more fre-
quent during sorafenib therapy, while mucositis/
stomatitis seem to occur more often during lenvatinib 
treatment. AEs occur at a median time of 3–12 weeks af-
ter the start of the MKIs and, generally, the frequencies 
of AEs are higher in the earlier cycles of treatment and 
diminish over the course of treatment [29], indicating 
that they may be self-limiting in some cases. The re-
sponse to toxicities should include therapies to rapidly 
Table 1. Parameters to be evaluated at baseline and at each control 
visit
Parameters to be evaluated
Clinical 
data
Weight, appetite, fatigue, diarrhoea, skin 
manifestations, patient’s diary on side effects and/
or symptoms
Blood tests TSH, fT4 (thyroglobulin, Tg antibodies at 
periodical intervals)
Electrolytes (Ca, Na, K, Mg)
Full blood count 
ALT, ALP, GGT
Glucose, total HDL, LDL cholesterol, triglycerides
Cardiac 
parameters
ECG (QTc interval)
Blood pressure 
Imaging Whole-body imaging (CT scan with contrast 
medium and/or MRI and/or 18-FDG-PET/CT 
scan) (first visit, then periodical evaluation 
metastatic sites)
Bone scintigraphy (optional) 
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and effectively reduce the AEs. Nevertheless, there are 
some AEs such as weight loss and anorexia that are very 
difficult to manage and require the reduction of the dai-
ly dose, if not the complete interruption of the drug, 
though every effort should be made to optimize tolerance 
and maintain the highest dosage level that is reasonably 
tolerable and effective in each patient. 
Hypertension
It is a frequent AE of MKI treatment and often is grade 
2 or 3. Interestingly, recent data in patients with RAI-R 
TC treated with lenvatinib showed that hypertension sig-
nificantly correlated with improved outcomes, indicating 
that it may be predictive of drug efficacy [68]. Blood pres-
sure and left ventricular ejection fraction should be mea-
sured and optimized before starting treatment. The 
choice of the antihypertensive drug should be individual-
ized, using angiotensin-converting enzyme inhibitors 
and/or calcium channel blockers, alone or in association, 
as the first-line drugs. If this is not effective, a diuretic 
should be added, electrolytes monitored, and dehydra-
tion avoided. Patients should check their blood pressure 
at home, with a daily or biweekly frequency, in order to 
allow a closer monitoring and titration of antihyperten-
sive therapy, with a target blood pressure ≤140/90 mm 
Hg (lower in case of overt proteinuria).
Diarrhoea
It is an extremely frequent AE, involving around 80% 
of patients taking MKIs, and is likely one of the most dis-
abling when the degree of severity is high [13]. It occurs 
mostly as grade 1 or grade 2, has a slow onset, and is typ-
ically intermittent (2 or 3 episodes per week) [26, 29]. 
When the degree of severity is < 3, it can be managed with 
dietary adjustments, with fluid and electrolyte replace-
ment, usually accompanied by pharmacological interven-
tions (such as loperamide, amisulpride, codeine). Some 
patients report benefits upon intermittent or prophylac-
Table 2. Frequency of the most frequent adverse events in patients treated with sorafenib and lenvatinib, accord-
ing to phase II, phase III registration, and real life studies [13, 15–19, 29, 65, 66]
Side effect Grade Frequency on sorafenib, %a Frequency on lenvatinib, %a
Hypertension Any grade
Grade 3–4
41/31 (19–42)
10/20 (2–38)
68/75 (67–80)
42/32 (10–49)
Diarrhoea Any grade
Grade 3–4
69/54 (47–63)
6/7 (1–13)
59/58 (45–67)
8/25 (1–42)
Weight loss Any grade
Grade 3–4
47/30 (1–58)
6/9 (0–17)
46/68 (46–92)
10/11 (5–17)
Fatigue Any grade
Grade 3–4
50/50 (30–69)
6/7
59/55 (44–61)
9/8 (5–10)
Anorexia/nausea Any grade
Grade 3–4
32/13 (7–21)
2/1
41/50 (18–75)
2/4 (1–8)
Mucositis/stomatitis Any grade
Grade 3–4
23/38 (27–48)
1/20
36/41 (24–58)
4/5 (2–8)
Palmar-plantar 
erythrodysaesthesia 
Any grade
Grade 3–4
76/72 (69–76)
20/26 (20–32)
32/29 (26–33)
3/2 (1–3)
Proteinuria Any grade
Grade 3–4
–
–
31/44 (32–64)
10/12 (10–13)
Skin rash Any grade
Grade 3–4
50/38 (25–55)
5/16 (3–29)
16/16
0.4/1
Alopecia Any grade
Grade 3–4
67/38 (31–52)
–
–
–
Increased TSH 33/26 –/44 (21–67)
a Registration/real life (range).
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tic consumption of natural remedies such as aloe or pro-
biotics. In case of grade 3 or 4, a dose reduction or inter-
ruption until diarrhoea returns to grade 1 is needed. 
Weight Loss
It is one of the most important AEs on MKIs, particu-
larly frequent in the real-life experiences with lenvatinib 
(Table 2). Anorexia in general or limited to some foods is 
frequent, and together with diarrhoea is one of the main 
causes of weight loss. Further AEs can contribute to 
weight loss, such as dysgeusia, oral mucositis, dyspepsia, 
and nausea which can improve by treatment with meto-
clopramide or serotonin receptor antagonists. MKIs seem 
to mostly affect muscular mass, but the fat mass is in-
volved too [69–71]. Anorexia and weight loss should be 
carefully managed by nutritional assessment at baseline 
and then periodically, always with the support of an ex-
pert nutritionist. Oral protein-rich, hypercaloric supple-
ments (200–250 kcal/100 ml) should be given at the first 
demonstration of weight loss, eventually associated with 
antioxidants. Enteral nutrition (1,000–1,200 kcal/L) 
should be given in more severe cases.
Fatigue
It is one of the most common and probably one of the 
most disabling AE observed during MKI treatment. In 
the registration studies [13, 14] as well as in real-life 
studies [15–19], fatigue was recorded in around 50–70% 
of patients, and it was a common reason for drug dis-
continuation or dose reduction. Several recommenda-
tions are given to patients, such as exercising (to main-
tain muscle mass), taking caffeine, MKI intake in the 
evening, monitoring electrolytes, haemoglobin, and 
TSH, maintaining hydration and adequate food intake, 
but in most cases these recommendations are not effec-
tive. It has been recently reported that primary adrenal 
insufficiency (PAI) occurs frequently in patients treated 
with lenvatinib, and that replacement treatment with 
cortisone acetate consequently leads to relief of fatigue 
[72]. 
Dermatological AEs
Cutaneous alterations, such as the palmar-plantar 
erythrodysaesthesia syndrome (“hand-foot syndrome”), 
are rare during lenvatinib treatment, but extremely fre-
quent under sorafenib, being the most common reason 
for dose reduction, interruption, and withdrawal [13] 
(Fig. 3). 
The intensity is variable and increases in the first 
months of therapy with a progressive decrease thereafter. 
The skin of hands and feet should be in optimal condi-
tions before starting MKI treatment by using urea-based 
creams and ensuring removal of hyperkeratotic lesions 
from hands and feet prior to MKI therapy. Management 
includes keeping hands and feet well hydrated, wearing 
comfortable shoes, avoiding hot water and trauma, re-
moving calluses, and using pain medication as needed. In 
more severe cases, ibuprofen (600 mg three times a day) 
can be prescribed, though dose reduction or short inter-
ruptions of MKIs can be required. Skin rash/sun burn 
after outdoor activities are also underestimated AEs and 
can be prevented by avoiding direct sunlight exposure, 
wearing protective clothing, including a hat and using 
sunblock (UF ≥50).
Mucositis/Stomatitis
Oral AEs usually occur within 2–4 weeks of initiating 
therapy. Oral hygiene and frequent mouthwash with wa-
ter and baking soda, high-molecular-weight hyaluronic 
acid, or aloe vera extracts are recommended. Topical an-
a b c
Fig. 3. Palmar-plantar erythrodysaesthesia syndrome (“hand-foot-syndrome”) (a and b) and alopecia of the eye-
brows (c) in a patient treated with sorafenib. 
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algesics alone or in combination (lidocaine 2%, diphen-
hydramine, bismuth subsalicylate, aluminum or magne-
sium hydroxide) can be used in more severe cases.
Proteinuria
Baseline and periodic assessment of urinary protein 
excretion is mandatory particularly in lenvatinib treat-
ment. Angiotensin-converting enzyme inhibitors or an-
giotensin receptor antagonist are generally effective. In 
the rare occurrence of nephrotic syndrome, MKI treat-
ment must be temporarily discontinued [73].
Increase in TSH Levels
Thyroid function should be monitored every 1–2 
months since thyroxine dosage needs to be increased in 
many TC patients on MKIs [74, 75].
Delay in Wound Healing
Inhibition of the VEGFR signalling pathway impairs 
angiogenesis and can delay the wound healing process. It 
is thus recommended to withdraw MKI treatment 3–10 
days before and after surgery or tooth extraction, depend-
ing on the extent of the procedure. 
Rare AEs
Some rare AEs are the consequence of MKI-induced 
hypertension, such as congestive heart failure [76], haem-
orrhage, and cardiac infarction [77]. Arterial thrombotic 
events, in particular acute coronary syndrome, require 
immediate cardiological treatment. The occurrence of ar-
terial thrombotic events may require permanent drug 
withdrawal. Venous thrombotic events should be man-
aged by low-molecular-weight heparin. Alterations in 
a b c d
blood cell count can occur during MKI treatment, and in 
most cases are grade 1 and 2 AEs [67, 78]. Arthralgias and 
myalgias occur in around 10% of patients and can be 
managed by analgesia and if required corticosteroid ther-
apy. Hoarseness has been reported in around 15% of len-
vatinib-treated patients.
A rare but severe AE is the reversible posterior leuko-
encephalopathy syndrome. At onset, neurological symp-
toms can be observed, and alterations of the white mat-
ter, consistent with toxic encephalopathy, can be docu-
mented on cranial MRI. MKI treatment must be stopped 
and a “restitution ad integrum” is usually observed with-
in 2–3 weeks (Fig. 4). A range of potentially serious gas-
trointestinal (GI) tract AEs, such as haemorrhage, intes-
tinal perforation and GI and non-GI (i.e., tracheal or oe-
sophageal) fistulas can be observed [79]. The risk of 
intestinal perforation with MKIs is probably higher in 
patients with a history of bowel conditions, such as coli-
tis or diverticulitis, and tracheal or oesophageal fistulas 
preferentially occur at site of previous surgery or irradia-
tion. Treatment must be discontinued if a perforation or 
a fistula occurs. Lenvatinib-induced renal failure has re-
cently been reported, due to glomerular damage with 
proteinuria or tubulointerstitial injury without protein-
uria [80].
The broad range and potential severity of MKI-related 
toxicities underscore the importance of proactive moni-
toring for, early recognition of, and expeditious response 
to emerging toxicities. Education should be provided to 
each patient before starting an MKI treatment. Some of 
the expected AEs can be prevented with an appropriate 
patient history and physical examination and with the 
precise information of the patient and of her/his family 
Fig. 4. The rare adverse event called reversible posterior leukoencephalopathy syndrome. a, b Brain MRI showed 
a posterior periventricular white matter hyperintensity and a signal alteration of the white matter interior of the 
cerebellum, confirming the diagnosis of toxic encephalopathy. c, d Brain MRI performed after 2 weeks of lenva-
tinib withdrawal documented an almost complete resolution of the radiological alterations, allowing to re-intro-
duce the MKI.
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members, e.g. as documented in the patient’s diary (see 
also the section Duration of Treatment and Follow-Up). 
Appropriate actions should be taken as soon as the symp-
toms appear, in order to promptly and effectively manage 
the AE, thus avoiding drug discontinuation.
Recommendation
[R28] An accurate multidisciplinary evaluation of the clinical 
features of the patient should be performed before starting MKIs.
[R29] Patient and carer education regarding potential toxicities 
and their management should be provided prior to initiation of 
treatment.
[R30] Patients must be instructed to report AEs, even when 
they are still low grade.
[R31] Patients must be treated by a TC specialist within an 
MDT and timely and effective supportive care and MKI dose ad-
justment should be given as needed.
[R32] Clinical and biochemical controls (including clinical ex-
amination, evaluation of AEs, blood count, urine analysis, renal 
and hepatic function, TSH, calcium) must be performed every 2 
weeks during the first 2 months of treatment. 
[R33] In order to limit the number of visits and to increase the 
compliance of patients, it is suggested to establish a dedicated con-
tact number.
[R34] Every effort and intervention should be made in order to 
limit dose reduction and to avoid drug discontinuation.
Palliative Treatments
The vast majority of TC cases are diagnosed at an ear-
ly stage when it is curable. However, RAI-R DTC has a 
poor prognosis with a median survival of less than 5 years 
and with disease progression is frequently associated with 
a reduction in quality of life due to debilitating symptoms. 
Advanced TC presents specific management issues. 
The anatomical site of locally advanced disease in the 
neck may cause airway compromise, dysphagia, and dys-
phonia and is often visible providing a constant reminder 
to the patient of their disease. Distant metastatic disease 
causes symptoms according to site such as pain, skeletal 
fracture, breathlessness, or organ obstruction. Some pa-
tients will have been living with their disease in an indo-
lent phase for many years, and the psychological impact 
of accepting the change in the nature of their disease to 
an aggressive, symptomatic phase can be difficult to deal 
with.
Specialists in palliative care medicine have expertise in 
managing multiple complex symptoms, psychosocial 
support, and assistance with decision making [81]. The 
involvement of the palliative care team in a patient’s man-
agement at an earlier time than the end of life phase is 
extremely beneficial in terms of both quality and quan-
tity of life for the patient [81] and their carers. A relation-
ship can be developed between clinician and patient with 
an understanding of patients’ wishes and concerns. This 
should lead to a more controlled and hopefully more 
comfortable life with advanced disease. 
The typical long natural history of the disease means 
that many patients will have had multiple treatments 
over many years, and hence the management of ad-
vanced TC requires a case-by-case approach with an in-
dividualized management plan. An assessment of the pa-
tient should include a full history of the current symp-
toms, impact on quality of life and any concerns or 
worries the patient may have. Specific symptoms may be 
addressed with locally ablative therapies that will not al-
ter the overall natural history of the disease but may pro-
vide significant symptom relief. Modalities such as sur-
gery, radiotherapy, vertebroplasty, and interventional 
radiology including radiofrequency ablation and embo-
lization may all be considered either alongside systemic 
therapies or alone [44, 47, 52, 54] (see also the section 
Local Treatments). Intervention for symptomatic, or im-
minently problematic, metastases in advanced TC should 
be considered because prognosis may still be measured 
in years, and therefore symptom control is critical to en-
suring an optimal quality of life. Moreover, if individual 
sites of problematic disease can be controlled locally, the 
initiation of systemic therapies and their associated tox-
icities may be delayed. Systemic therapies for advanced 
disease are discussed in the sections When to Start Treat-
ment with MKIS? to Management of Side Effects. In ad-
dition to targeted therapies to modulate the disease pro-
cess, a systemic approach to bone metastases should be 
considered. Bone metastases can be detected in around 
4% of patients and a skeletal-related event (SRE), which 
is an independent poor prognostic factor, in around 5.5% 
[82]. Medical management with bisphosphonates, spe-
cifically zoledronate, is recommended based on data ex-
trapolated from other solid tumours [83, 84], and a ben-
eficial effect has been documented also in TC patients 
[85]. There is some evidence that denosumab, a human, 
monoclonal, IgG2 antibody that binds to RANKL and 
inhibits osteoclasts, bone destruction, and tumour 
growth, is more effective than zoledronate in preventing 
SREs in solid tumours [86, 87]. It is worth noting that 
denosumab can cause hypocalcaemia and osteonecrosis 
of the jaw, with a higher risk if the patient is on MKIs, but 
has less impact on renal function and fewer acute phase 
reactions. 
Fugazzola/Elisei/Fuhrer/Jarzab/
Leboulleux/Newbold/Smit
Eur Thyroid J 2019;8:227–245242
DOI: 10.1159/000502229
Recommendation
[R35] Early involvement of the palliative care team is encour-
aged to optimize symptom control and psychosocial support in 
patients with advanced TC.
[R36] Consideration should be given to locally ablative thera-
pies to palliate specific symptoms.
[R37] Consideration should be given to the systemic manage-
ment of bone metastases to minimize SREs.
Ethical Considerations
ATA Clinical and Professional Ethics Guidelines for 
The Practice of Thyroidology, published in 2013, sum-
marized the ethics principles that physicians should fol-
low in their clinical practice [88]. Daily ethical duties to 
patients should be based on equality, competence, cul-
tural values, physician-patient communication and 
should consider conflicts of interest, sexual relationships, 
privacy and confidentiality, treatment of family members 
(physicians should not treat their families), and main-
taining ethical integrity in unethical environments [88]. 
Informed consent, involving full information on dis-
ease status, planned treatment, its consequences and pos-
sible side effects, plays a crucial role in a treatment deci-
sion-making process. One should always respect the pref-
erence of autonomous patients, their acceptance or 
refusal of recommended therapies. On the other hand, 
any pressure from family members or from a patient, to 
treat regardless the lack of its efficacy or potential risk, 
should have no impact on the decision-making process. 
There are some important ethical issues that the physi-
cians managing advanced TCs have to face. The first one 
is how to inform the patients about a potentially lethal 
disease. According to the ATA Guidelines, the following 
issues should be discussed: prognosis, both with and with-
out treatment, therapeutic options, so-called “code status” 
(patient decision regarding cardiopulmonary resuscita-
tion, nutrition, hydration, and intubation), palliative care, 
hospice care, physical/medical order for life-sustaining 
treatment, and other patient’s “advance directives” [88]. 
The decision on the appropriateness of a palliative treat-
ment, or of a cardiopulmonary resuscitation, should be 
physicians’ responsibility, though patient’s opinion should 
be considered. Our ethical responsibility is to provide pa-
tients with objective, evidence-based information related 
to their individual disease status rather than assuming 
what is the best for an individual patient by selectively 
withholding known information [89]. However, one has 
to be aware that precise data on a poor prognosis and lim-
ited treatment options might be particularly stressful for 
the patients and extremely difficult to accept and simulta-
neously not to lose hope. Therefore, the support of a psy-
chologist and/or of a specialized nurse should be consid-
ered and offered to the patients. In this context, it is also 
worth mentioning that patients with advanced disease 
should be treated at or in collaboration with specialized 
centres with all needed disciplines available.
Other important clinical questions to consider in-
volve: “to treat or not to treat,” “which treatment to 
choose: conventional or experimental” or “when to start 
or stop the treatment.” 
Answering the questions “to treat or not to treat” and 
“which treatment to choose: conventional or experimen-
tal” one should consider evidence-based data on treat-
ment efficacy, its impact on progression-free and overall 
survival, and on the quality of life, life expectancy, comor-
bidities, and risk/benefits ratio. The question “when to 
start the treatment” may also infer ethical dilemma. It 
should be emphasized that evidence-based medicine sup-
ports treatment initiation in patients with bulky, imme-
diately life-threatening or progressive disease. Another 
question “when to stop the treatment” seems to be even 
more important. Is disease progression a sufficient condi-
tion to stop the treatment? It is believed that the with-
drawal of MKI may speed up disease progression; hence, 
it could be better to continue treatment, if there are no 
other therapeutic options, than to withdraw it. However, 
since MKI treatment is not inexpensive, this decision can 
pose an ethical dilemma. 
Recommendation
[R38] The management of patients with advanced RAI-R TC 
should respect general ethical principles, such as: equality, compe-
tence, cultural values, physician-patient communication, privacy 
and confidentiality, and conflicts of interest. Physicians are obliged 
to respect autonomous patients’ preference.
[R39] Once approved therapies have failed or if there are rea-
sons for rejecting them, patients with advanced TC should be treat-
ed preferably within randomized clinical trials to provide evi-
dence-based data on adequate therapeutic approach.
Conclusions and Perspectives
Advanced RAI-R TC represents a challenging condi-
tion. In the last decade, novel local and systemic treat-
ments have been made available to specialists. However, 
the real-life practice has taught us that these complex TC 
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patients must be managed by a multidisciplinary board of 
physicians, and always by specialized nurses. The board 
should initially include specialists in endocrinology, en-
docrine oncology, endocrine surgery, pathology, radiol-
ogy, nuclear medicine, and interventional radiology. Af-
ter the start of the MKI treatment, the board should also 
include specialists in psychology, nutritional medicine, 
dermatology, and cardiology. 
Several novel and promising perspectives are available 
for the treatment of advanced TC. Ongoing studies are 
evaluating the efficacy and safety of new MKIs, rediffer-
entiation therapies, and of immunotherapeutic com-
pounds to be used alone or in combination, as first or 
second and third-line treatments.
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